var data={"title":"Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/479790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">see &quot;Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Drug information&quot;</a> and <a href=\"topic.htm?path=rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186898\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">HIV-1 and hepatitis B coinfection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Emtricitabine/rilpivirine/tenofovir disoproxil fumarate is not approved for the treatment of chronic hepatitis B virus (HBV) infection, and safety and efficacy have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued emtricitabine or tenofovir disoproxil fumarate. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue antiretroviral treatment. If appropriate, initiation of anti-HBV therapy may be warranted.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168282\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Complera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13455802\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Complera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24943779\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral, Reverse Transcriptase Inhibitor, Non-nucleoside (Anti-HIV)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24943784\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">see &quot;Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Age &lt;12 years or weight &lt;35 kg: Not recommended; product is a fixed-dose combination</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents weighing &ge;35 kg: Oral: One tablet once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant therapy with rifabutin:</b> Children &ge;12 years and Adolescents weighing &ge;35 kg: Oral: One tablet once daily plus rilpivirine 25 mg once daily</p>\n    <p style=\"text-indent:0em;\">Adult: <b> HIV-1 infection, treatment:</b> Adults &ge;35 kg: Oral: One tablet once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clcr &ge;50 mL/minute: No dosage adjustments necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clcr &lt;50 mL/minute: Use is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD requiring dialysis: Use is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustments necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168283\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Complera: Emtricitabine 200 mg, rilpivirine 25 mg, and tenofovir disoproxil fumarate 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186899\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24943785\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with a meal of at least 500 calories (HHS [pediatric] 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186920\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in original container. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24943780\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection (as a complete regimen) in antiretroviral treatment-naive patients with HIV-1 RNA &le;100,000 copies/mL at the start of therapy, and in certain virologically suppressed (HIV-1 RNA &lt;50 copies/mL) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (FDA approved in ages &ge;12 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708021\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186917\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Observed in patients receiving the same doses of emtricitabine, rilpivirine, and tenofovir as the combination product; also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenocortical insufficiency (not associated with any serious events), increased LDL cholesterol, increased serum cholesterol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal dreams, anxiety, cholecystitis, cholelithiasis, diarrhea, dizziness, drowsiness, fatigue, glomerulonephritis (membranous and mesangioproliferative), hypersensitivity reaction, immune reconstitution syndrome, increased serum triglycerides (&ge;500 mg/dL), nausea, nephrolithiasis, nephrotic syndrome, vomiting, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186905\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent use of carbamazepine, systemic dexamethasone (&gt;1 dose), oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors (PPIs) (eg, dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole), rifampin, rifapentine, and/or St John's wort.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to emtricitabine, rilpivirine, tenofovir disoproxil fumarate or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186906\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac effects: In healthy subjects, supratherapeutic dosages of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QTc interval of the electrocardiogram; use caution when coadministering with drugs with a known risk of torsades de pointes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: In clinical trials, tenofovir disoproxil fumarate has been associated with decreases in bone mineral density in HIV-1 infected adults and increases in bone metabolism markers. Serum parathyroid hormone and 1,25 vitamin D levels were also higher. Decreases in bone mineral density have also been observed in clinical trials of HIV-1 infected pediatric patients. Observations in chronic hepatitis B infected pediatric patients (aged 12 to 18 years) were similar. In all pediatric clinical trials, skeletal growth (height) appears unaffected. Consider monitoring of bone density in adult and pediatric patients with a history of pathologic fractures or with other risk factors for bone loss or osteoporosis. Consider calcium and vitamin D supplementation for all patients; effect of supplementation has not been studied but may be beneficial. Long-term bone health and fracture risk unknown. If abnormalities are suspected, expert assessment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depressive disorders: Rilpivirine may cause depression, depressed mood, dysphoria, major depression, mood changes, negative thoughts, suicide attempts, or suicidal ideation. Promptly evaluate patients with severe depressive symptoms and reevaluate risk versus benefit of continued combination therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity has been reported with rilpivirine-containing regimens. Patients with hepatitis B or C or increased baseline liver function tests may be at greater risk, although some cases have occurred in patients with no preexisting disease or hepatic disease risk factors. Evaluate liver function tests in patients with increased baseline liver function tests or with hepatitis B or C prior to treatment initiation and periodically during therapy; also consider evaluation of patients with no preexisting hepatic disease or hepatic disease risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and severe skin reactions have been reported, including severe rash or rash accompanied by fever, blisters, mucosal involvement, conjunctivitis, facial edema, angioedema, hepatitis or eosinophilia, or drug reaction with eosinophilia and systemic symptoms (DRESS) with regimens containing rilpivirine. Some skin reactions were accompanied by constitutional symptoms (eg, fever); other skin reactions were associated with organ dysfunction (eg, hepatic serum biochemistry elevations). In clinical trials, treatment-related rashes &ge; grade 2 were reported in 1% of patients. Most rashes were Grade 1 or 2 and occurred within the first 4 to 6 weeks of therapy. Monitor laboratory parameters and clinical status; discontinue if any severe hypersensitivity or skin rash develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly, sometimes fatal, have been reported with the use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteomalacia and renal dysfunction: Tenofovir disoproxil fumarate may cause osteomalacia with proximal renal tubulopathy. Bone pain, extremity pain, fractures, arthralgias, weakness, and muscle pain have been reported. In patients at risk for renal dysfunction, persistent or worsening bone or muscle symptoms should be evaluated for hypophosphatemia and osteomalacia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID use). Acute renal failure has occurred in HIV-infected patients with risk factors for renal impairment who were on a stable tenofovir disoproxil fumarate regimen to which a high dose or multiple NSAID therapy was added. Consider alternatives to NSAIDS in patients taking tenofovir disoproxil fumarate and at risk for renal impairment. Calculate estimated CrCl prior to initiation of therapy and as clinically appropriate during therapy. In patients at risk for renal dysfunction, including patients who have experienced renal events while taking adefovir, also assess serum phosphorus, urine glucose, and urine protein prior to and periodically during treatment. IDSA guidelines recommend discontinuing tenofovir (and substituting with alternative antiretroviral therapy) in HIV-infected patients who develop a decline in GFR (a &gt;25% decrease in GFR from baseline and to a level of &lt;60 mL/minute/1.73 m<sup>2</sup>) during use, particularly in presence of proximal tubular dysfunction (eg, euglycemic glycosuria, increased urinary phosphorus excretion and hypophosphatemia, proteinuria [new onset or worsening]) (IDSA [Lucas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: Safety and efficacy during coinfection of HIV-1 and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of antiretroviral therapy. Not indicated for treatment of chronic hepatitis B. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue this therapy. If appropriate, anti-hepatitis B therapy may be warranted.</b> All patients with HIV should be tested for HBV prior to initiation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use is not recommended in patients with CrCl &lt;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concurrent therapy: Avoid concurrent use with adefovir or lamivudine-containing products or other emtricitabine-, rilpivirine-, and/or tenofovir-containing products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patients with increased HIV-1 viral loads (HIV-1 RNA &gt;100,000 copies/mL) or CD4+ cell counts &lt;200 cells/mm<sup>3</sup> at treatment initiation are more likely to develop treatment failure (Cohen 2011; HHS [adult] 2015; Molina 2011). Therefore, rilpivirine-based regimens should not be used in adolescent and adult HIV-1 patients with a pre-ART CD4 count &lt;200 cells/mm<sup>3</sup> and/or HIV RNA &gt;100,000 copies/mL (HHS [adult] 2015). Rilpivirine resistance patterns are very similar to those of etravirine (including cross resistance with single substitutions at K101P, Y181I, and Y181V) (Azijn 2010). When used to replace an antiretroviral treatment regimen in virologically-suppressed patients currently on a stable regimen, patients must have no history of virologic failure; prior to regimen replacement, must have been suppressed for at least 6 months; must be currently on their first or second antiretroviral regimen, and have no history of resistance to emtricitabine, rilpivirine, or tenofovir.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring: If used as therapy replacement in virologically suppressed patients meeting criteria, additional HIV-1 RNA and regimen tolerability monitoring is recommended to assess potential virologic failure or rebound.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46780383\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults (children: 32%; adults: 2% to 6%). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Recent studies suggest that tenofovir-related bone loss may be greater in children who are less mature (eg, Tanner stage 1 to 2) than in those who are more physically mature (Tanner &ge;3). A significant decrease in lumbar spine BMD (&gt;6%) was reported in five of 15 pediatric patients who received a tenofovir disoproxil fumarate-containing regimen for 48 weeks. No orthopedic fractures occurred, but two patients required discontinuation of tenofovir. All five patients with a decrease in BMD were virologic responders and prepubertal (Tanner Stage 1). This study found a moderately strong correlation between decreases in bone mineral density z scores at week 48 and age at baseline. No correlation between decreases in bone mineral density z scores and tenofovir dose or pharmacokinetics was observed; BMD loss may limit the usefulness of tenofovir in prepubertal children (Giacomet 2005; Hazra 2005; Purdy 2008). Monitor BMD for potential bone toxicities during therapy; supplementation with calcium and vitamin D may be beneficial but has not been studied. <b>Note:</b> The sexual maturity rating (SMR) has replaced Tanner staging to identify puberty stages in adolescent patients (HHS [pediatric] 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299262\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13225897\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=108894&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Rilpivirine. Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine. Administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.  Management: Must use ritonavir-boosting in adults; give combo (atazanavir/ritonavir 300mg/100mg and tenofovir 300mg) as a single daily dose with food.  Pediatric patients, pregnant patients, and users of H2-blockers require other dose changes.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May enhance the adverse/toxic effect of Tenofovir Products. More specifically, cobicistat may impair proper tenofovir monitoring and dosing.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: Tenofovir Disoproxil Fumarate may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to this combination whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Tenofovir Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenofovir Disoproxil Fumarate may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir disoproxil fumarate and didanosine.  Consider altering even existing, stable treatment to avoid this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergonovine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Rilpivirine. Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Rilpivirine. Rilpivirine may decrease the serum concentration of Ketoconazole (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate. Management: Avoidance of this combination is recommended under some circumstances.  Refer to full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May enhance the nephrotoxic effect of Tenofovir Disoproxil Fumarate. Lopinavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of Rilpivirine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Rilpivirine. Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Rilpivirine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Rilpivirine. Management: Increase the rilpivirine adult dose to 50 mg/day during rifabutin treatment. Decrease back to 25 mg/day following rifabutin discontinuation.  Use of rifabutin with the emtricitabine/rilpivirine/tenofovir alafenamide combination product is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Rilpivirine.<b> Exceptions: </b>Rifabutin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24528938\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186901\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186902\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider emtricitabine in combination with rilpivirine and tenofovir disoproxil fumarate to be an alternative NNRTI regimen for initial use in antiretroviral-naive pregnant females with a pre-treatment HIV RNA &le;100,000 copies/mL or CD4 cell count &ge;200 cells/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, females who become pregnant on a stable antiretroviral therapy (ART) regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24943786\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for initiation of antiretroviral treatment (HHS [pediatric] 2015). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Screen for hepatitis B before starting emtricitabine therapy (in patients who previously demonstrated no immunity to hepatitis B). Also prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: Hepatitis B screening (at change in therapy, in patients who previously demonstrated no immunity to hepatitis B), CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load, and screen for hepatitis B. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Lipid panel and urinalysis every 6 to 12 months. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2016). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, or lactic acidosis. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients with HIV and HBV coinfection should be monitored for several months following tenofovir discontinuation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186921\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Non-nucleoside, nucleoside, and nucleotide reverse transcriptase inhibitor combination; rilpivirine binds to reverse transcriptase and does not require intracellular phosphorylation for antiviral activity; emtricitabine is a cytosine analogue while tenofovir disoproxil fumarate (TDF) is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186923\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Using the combination tablet, the C<sub>max</sub> and AUC of rilpivirine increased 34% and 9% when taken with a light meal (390 kcal; 12 g fat) and 26% and 16% when taken with a standard meal (540 kcal; 21 g fat); tenofovir C<sub>max</sub> and AUC increased 12% and 28% with a light meal and 32% and 38% with a standard meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Also see individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322911\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Complera Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-25-300 mg (30): $3,216.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14190116\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Complera (AR, CL, HK, JP, SG);</li>\n      <li>Eviplera (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, IE, IL, IS, LT, LU, MT, NL, NO, NZ, PL, PT, SE, SI, SK);</li>\n      <li>Komplera (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Azijn H, Tirry I, Vingerhoets J, et al, &ldquo;TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active Against Wild-Type and NNRTI-Resistant HIV-1,&rdquo; <i>Antimicrob Agents Chemother</i>, 2010, 54(2):718-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/19933797/pubmed\" target=\"_blank\" id=\"19933797\">19933797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen CJ, Andrade-Villanueva J, Clotet B, et al, &quot;Rilpivirine Versus Efavirenz With Two Background Nucleoside or Nucleotide Reverse Transcriptase Inhibitors in Treatment-Naive Adults Infected with HIV-1 (THRIVE): A Phase 3, Randomized, Non-Inferiority Trial,&quot; <i>Lancet</i>, 2011, 378(9787):229-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/21763935/pubmed\" target=\"_blank\" id=\"21763935\">21763935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Complera (emtricitabine, rilpivirine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigan&ograve; A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. <i>J Acquir Immune Defic Syndr</i>. 2005;40(4):448-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/16280700 /pubmed\" target=\"_blank\" id=\"16280700 \">16280700 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. <i>Pediatrics</i>. 2005;116(6):e846-854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/16291735/pubmed\" target=\"_blank\" id=\"16291735\">16291735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 1, 2016. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services. Updated April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf%20\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf </a>. Updated October 26, 2016. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Supplemental information regarding the role of rilpivirine (RPV) as initial therapy &ndash; August 16, 2011. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/NNRTI_One_Page_Info-RPV.pdf%20\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/NNRTI_One_Page_Info-RPV.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/25234519 /pubmed\" target=\"_blank\" id=\"25234519 \">25234519 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. <i>J Pediatr</i>. 2008;152(4):582-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/18346519 /pubmed\" target=\"_blank\" id=\"18346519 \">18346519 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacArthur RD, &ldquo;Clinical Trial Report: TMC278 (Rilpivirine) versus Efavirenz as Initial Therapy in Treatment-Naive, HIV-1-Infected Patients,&rdquo; <i>Curr Infect Dis Rep</i>, 2011, 13(1):1-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/21308448/pubmed\" target=\"_blank\" id=\"21308448\">21308448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molina JM, Cahn P, Grinsztejn B, et al, &quot;Rilpivirine Versus Efavirenz With Tenofovir and Emtricitabine in Treatment-Naive Adults Infected With HIV-1 (ECHO): A Phase 3 Randomized Double-Blind Active-Controlled Trial,&quot; <i>Lancet</i>, 2011, 378(9787): 238-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/21763936/pubmed\" target=\"_blank\" id=\"21763936\">21763936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pozniak AL, Morales-Ramirez J, Katabira E, et al, &ldquo;Efficacy and Safety of TMC278 in Antiretroviral-Na&iuml;ve HIV-1 Patients: Week 96 Results of a Phase IIb Randomized Trial,&rdquo; <i>AIDS</i>, 2010, 24(1):55-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/19926964/pubmed\" target=\"_blank\" id=\"19926964\">19926964</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 108894 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13186898\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13168282\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13455802\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F24943779\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F24943784\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13168283\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F13186899\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24943785\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F13186920\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24943780\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708021\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13186917\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13186905\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13186906\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46780383\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299262\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13225897\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F24528938\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13186901\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13186902\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24943786\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13186921\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F13186923\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322911\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14190116\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/108894|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Drug information</a></li><li><a href=\"topic.htm?path=rilpivirine-emtricitabine-and-tenofovir-disoproxil-fumarate-patient-drug-information\" class=\"drug drug_patient\">Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate: Patient drug information \t</a></li></ul></div></div>","javascript":null}